Pablo Parenti

ORCID: 0000-0002-5882-7073
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis C virus research
  • Public Health and Environmental Issues
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • HIV/AIDS Research and Interventions
  • Liver Disease Diagnosis and Treatment
  • Drug-Induced Hepatotoxicity and Protection
  • Bacillus and Francisella bacterial research
  • Poxvirus research and outbreaks
  • Pneumocystis jirovecii pneumonia detection and treatment
  • SARS-CoV-2 detection and testing
  • Ethics in Clinical Research
  • HIV, Drug Use, Sexual Risk
  • Hepatitis B Virus Studies
  • Zoonotic diseases and public health
  • Ethics and bioethics in healthcare
  • Folate and B Vitamins Research
  • Artificial Intelligence in Healthcare and Education

National University of Rosario
2012-2025

Hospital Provincial de Rosario
2021

Fundação Oswaldo Cruz
2016

University of Aruba
2016

Institute of Physics Rosario
2012

Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) alafenamide (TAF), both part of antiretroviral therapy (ART) regimens. People living with human immunodeficiency virus (PLWH) might at higher risk for progression; however, information about the impact on clinical outcomes remains controversial. The COVIDARE a prospective observational multicentric study in Argentina. PLWH were enrolled from September 2020...

10.3390/v15051127 article EN cc-by Viruses 2023-05-09

El artículo aborda los desafíos éticos y regulatorios del uso de inteligencia artificial (IA) en la investigación médica, enfatizando importancia un marco regulatorio que facilite el desarrollo ético seguro tecnología. Explora cómo IA, si bien permite automatización análisis grandes volúmenes datos con mayor precisión, también plantea preocupaciones éticas como sesgos algorítmicos amenazas a privacidad pacientes. A lo largo texto, se destaca necesidad equilibrio entre innovación control para...

10.22481/rbba.v14i2.15519 article ES cc-by-nc-sa Revista Binacional Brasil-Argentina Diálogo entre as ciências 2024-12-12

Background Antiretroviral drugs used to treat HIV may cause hepatotoxicity. The high prevalence of persons with chronic hepatitis B or C coinfected, raised aminotransferases have many causes and neither specific markers is a indicator liver injury, difficulties in interpreting the Objective We evaluated hepatotoxicity HIV/HCV‐ and/or HBV‐coinfected patients, risk factors severity. Methods Prospective study HIV‐1 patients start HAART Hospital Provincial del Centenario from Rosario, Argentina....

10.7448/ias.15.6.18431 article EN cc-by Journal of the International AIDS Society 2012-11-01

To document antiretroviral use in Latin America during the last decade.We collected indicators from 79 HIV health care centres 14 American Spanish-speaking countries for 2013-2017. Indicators were analysed by age, sex and other characteristics weighted estimated people under (PUC) population each country.We gathered information on 116 299 PUC. One-third belonged to reporting a shortage of at least one therapy (ART) drug >30 days 2017. At end 2017, 95.1% PUC receiving ART. During 2013-2017,...

10.1016/j.ijid.2021.09.047 article EN cc-by-nc-nd International Journal of Infectious Diseases 2021-09-24

The development of potent interferon-free regimens direct-acting antivirals (DAAs) for the treatment hepatitis C virus (HCV) infection has moved at a remarkable pace. Highly effective, extremely well-tolerated are now available most patient populations. Remarkably, advances have as quickly those with HIV–HCV co-infection HCV monoinfection, recent studies showing similar results in both This raised question whether HIV continues to represent “special” population among HCV-infected...

10.7448/ias.19.2.21083 article EN cc-by Journal of the International AIDS Society 2016-04-28

Introducción: Existe controversia con respecto a los factores que determinan un mayor riesgo de gravedad y complicaciones por COVID-19 en personas viven VIH (PVVIH). Asimismo, hay datos limitados sobre el impacto la vacunación contra SARS-CoV-2 hospitalización esta población.

10.4067/s0716-10182023000300236 article ES Revista chilena de infectología 2023-06-01

Background: Antiretroviral drugs used to treat HIV may cause hepatotoxicity. The high prevalence of persons with chronic hepatitis B or C coinfected, raised aminotransferses have many causes and neither specific markers is a indicator liver injury, difficulties in interpreting the Objective: We evaluated hepatotoxicity HIV/HVC and/or HBV coinfected patients, risk factors severity. Methods: Prospective study HIV-1 patients start HAART Hospital Provincial del Centenario from Rosario,...

10.1016/j.ijid.2012.05.754 article EN publisher-specific-oa International Journal of Infectious Diseases 2012-06-01
Coming Soon ...